サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1540996

多発性骨髄腫治療薬市場レポート：治療法、薬剤タイプ、エンドユーザー、流通チャネル、地域別、2024～2032年

Multiple Myeloma Drugs Market Report by Therapy, Drug Type, End-User, Distribution Channel, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 138 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
多発性骨髄腫治療薬市場レポート：治療法、薬剤タイプ、エンドユーザー、流通チャネル、地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の多発性骨髄腫治療市場規模は2023年に223億米ドルに達しました。今後、IMARC Groupは、2024～2032年の成長率（CAGR）は5.2％で、2032年には355億米ドルに達すると予測しています。

多発性骨髄腫（カーラー病）は、主に形質細胞を侵す血液がんの一種です。最も一般的な多発性骨髄腫治療には、化学療法剤、コルチコステロイド、免疫調節剤などがあります。これらの医薬品は、骨治癒を促進し、高カルシウム血症、骨折、脊髄圧迫、貧血を予防すると同時に、化学療法の必要性を最小限に抑えます。化学療法剤には、各種アントラサイクリン系抗生物質や、メルファラン、ドキソルビシン、ビンクリスチン、リポソームドキソルビシンなどのアルキル化剤が含まれます。標的治療には、ボルテゾミブなどのプロテアソーム阻害薬や、デキサメタゾン、プレドニゾン、サリドマイドなどの様々な化合物が含まれます。

血液がんの有病率の増加とともに、医療セグメントにおける大きな発展が、市場の成長を促す主要要因の一つとなっています。多発性骨髄腫は通常、特定の遺伝子異常によって引き起こされ、この疾患の治療には免疫系を調節し、化学療法、放射線療法、幹細胞移植、血小板輸血の効率を高めるのに役立つ薬剤が含まれます。さらに、骨髄腫細胞を識別して攻撃するために身体の免疫系を利用する生物製剤の利点に関する消費者の意識の高まりも、市場の成長を後押ししています。さらに、多発性骨髄腫治療のためのマイクロRNA治療やナノ医薬品の開発など、様々な技術的進歩がもう一つの成長促進要因として作用しています。これらの医薬品は、骨髄への高分子薬剤の送達を促進し、抗腫瘍反応を触媒するために使用されます。その他の要因としては、医療費の増加や医療科学セグメントにおける広範な研究開発活動などがあり、市場をさらに牽引すると予測されています。

本レポートで扱う主要質問

  • 世界の多発性骨髄腫治療市場はこれまでどのように推移し、今後どのように推移していくのか？
  • 主要な地域市場は？
  • COVID-19は世界の多発性骨髄腫治療市場にどのような影響を与えたか？
  • 治療法別の市場内訳は？
  • 薬剤タイプ別の市場内訳は？
  • エンドユーザー別の市場内訳は？
  • 流通チャネル別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界の多発性骨髄腫治療市場の構造と主要参入企業は？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 パイプライン評価/臨床試験製品/臨床開発

  • PegIntron（ペグインターフェロンアルファ-2b）
  • ポマリドミド
  • タネスピマイシン（KOS-953）
  • MLN9708
  • SRT-501-012
  • ＢＨＱ８８０
  • パノビノスタット
  • ZIO-101
  • VEGFトラップ（アフリベルセプト）
  • デノスマブ
  • ペリホシン
  • アクチミド（CC-5013）
  • ロミデプシン
  • プリチデプシン（アプリジン）
  • テムシロリムス（トリセル）
  • ソラフェニブ
  • ベバシズマブ

第6章 世界の多発性骨髄腫治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第7章 市場内訳：治療法別

  • 標的療法
  • 生物学的療法
  • 化学療法
  • その他

第8章 市場内訳：薬剤タイプ別

  • 免疫調節薬
  • プロテアソーム阻害剤
  • ヒストン脱アセチル化酵素阻害剤
  • モノクローナル抗体医薬品
  • ステロイド
  • その他

第9章 市場内訳：エンドユーザー別

  • 男性
  • 女性

第10章 市場内訳：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第11章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第12章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第15章 価格指標

第16章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amgen Inc.
    • Bristol Myers Squibb
    • Daiichi Sankyo Co.
    • Sanofi-Aventis Groupe（Genzyme Corporation）
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Novartis International AG
    • Pfizer Inc.
    • PHARMA MAR, S.A.
    • Takeda Pharmaceutical Company Limited.
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Multiple Myeloma Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Multiple Myeloma Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Multiple Myeloma Drugs Market: Breakup by Therapy (in %), 2023
  • Figure 4: Global: Multiple Myeloma Drugs Market: Breakup by Drug Type (in %), 2023
  • Figure 5: Global: Multiple Myeloma Drugs Market: Breakup by End-User (in %), 2023
  • Figure 6: Global: Multiple Myeloma Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Multiple Myeloma Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Multiple Myeloma Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 9: Global: Multiple Myeloma Drugs (Targeted Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Multiple Myeloma Drugs (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Multiple Myeloma Drugs (Biologic Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Multiple Myeloma Drugs (Biologic Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Multiple Myeloma Drugs (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Multiple Myeloma Drugs (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Multiple Myeloma Drugs (Steroids) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Multiple Myeloma Drugs (Steroids) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Multiple Myeloma Drugs (Men) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Multiple Myeloma Drugs (Men) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Multiple Myeloma Drugs (Women) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Multiple Myeloma Drugs (Women) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Multiple Myeloma Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Multiple Myeloma Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: North America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: North America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: United States: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: United States: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Canada: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Canada: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Asia Pacific: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Asia Pacific: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: China: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: China: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Japan: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Japan: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: India: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: India: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: South Korea: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: South Korea: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Australia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Australia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Indonesia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Indonesia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Europe: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Europe: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Germany: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Germany: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: France: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: France: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: United Kingdom: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: United Kingdom: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Italy: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Italy: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Spain: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Spain: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Russia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Russia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Latin America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Latin America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Brazil: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Brazil: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Mexico: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Mexico: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Middle East and Africa: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Middle East and Africa: Multiple Myeloma Drugs Market: Breakup by Country (in %), 2023
  • Figure 89: Middle East and Africa: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Global: Multiple Myeloma Drugs Industry: SWOT Analysis
  • Figure 91: Global: Multiple Myeloma Drugs Industry: Value Chain Analysis
  • Figure 92: Global: Multiple Myeloma Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Multiple Myeloma Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Therapy (in Million US$), 2024-2032
  • Table 3: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 4: Global: Multiple Myeloma Drugs Market Forecast: Breakup by End-User (in Million US$), 2024-2032
  • Table 5: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Multiple Myeloma Drugs Market Structure
  • Table 8: Global: Multiple Myeloma Drugs Market: Key Players
目次
Product Code: SR112024A2169

The global multiple myeloma drugs market size reached US$ 22.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 35.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5.2% during 2024-2032.

Multiple myeloma, or Kahler's disease, refers to a form of blood cancer that primarily affects the plasma cells. Some of the most common types of multiple myeloma drugs include chemotherapeutic agents, corticosteroids and immunomodulatory agents. These pharmaceutical drugs aid in promoting bone healing, prevent hypercalcemia, bone fracture, spinal cord compression and anemia, while minimizing the need for chemotherapy. The chemotherapeutic agents include various anthracycline antibiotics and alkylating agents, such as melphalan, doxorubicin, vincristine and liposomal doxorubicin. The targeted therapy drugs include proteasome inhibitor, such as bortezomib, and various other compounds, including dexamethasone, prednisone and thalidomide.

Significant developments in the healthcare sector, along with the increasing prevalence of hematological cancer, is one of the key factors driving the growth of the market. Multiple myeloma is usually caused by specific genetic abnormalities, and the treatment of this disease involves drugs that modulate the immune system and aid in enhancing the efficiency of chemotherapies, radiation therapies, stem cell transplants and platelet transfusion. Furthermore, rising consumer awareness regarding the benefits of biologic therapy drugs, which utilize the body's immune system to identify and attack the myeloma cells, is also providing a boost to the market growth. Additionally, various technological advancements, such as the development of microRNA therapeutics and nanomedicines for the treatment of multiple myeloma, is acting as another growth-inducing factor. These medicines are used to facilitate the delivery of macromolecular agents into the bone marrow and catalyze antitumor responses. Other factors, including the rising healthcare expenditures and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global multiple myeloma drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on therapy, drug type, end-user and distribution channel.

Breakup by Therapy:

Targeted Therapy

Biologic Therapy

Chemotherapy

Others

Breakup by Drug Type:

Immunomodulatory Drugs

Proteasome Inhibitors

Histone Deacetylase Inhibitors

Monoclonal Antibody Drugs

Steroids

Others

Breakup by End-User:

Men

Women

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., Bristol Myers Squibb, Daiichi Sankyo Co., Ltd., Sanofi-Aventis Groupe (Genzyme Corporation), Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., PHARMA MAR, S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., etc.

Key Questions Answered in This Report:

  • How has the global multiple myeloma drugs market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global multiple myeloma drugs market?
  • What is the breakup of the market based on the therapy?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the end-user?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global multiple myeloma drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Pipeline Assesment/Clinical Trial Products/Clinical Developments

  • 5.1 PegIntron (Pegylated interferon alfa-2b)
  • 5.2 Pomalidomide
  • 5.3 Tanespimycin (KOS-953)
  • 5.4 MLN 9708
  • 5.5 SRT-501- 012
  • 5.6 BHQ880
  • 5.7 Panobinostat
  • 5.8 ZIO-101
  • 5.9 VEGF-Trap(Aflibercept)
  • 5.10 Denosumab
  • 5.11 Perifosine
  • 5.12 Actimid (CC-5013)
  • 5.13 Romidepsin
  • 5.14 Plitidepsin (Aplidin)
  • 5.15 Temsirolimus (Torisel)
  • 5.16 Sorafenib
  • 5.17 Bevacizumab

6 Global Multiple Myeloma Drugs Market

  • 6.1 Market Overview
  • 6.2 Market Performance
  • 6.3 Impact of COVID-19
  • 6.4 Market Forecast

7 Market Breakup by Therapy

  • 7.1 Targeted Therapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biologic Therapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Chemotherapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Drug Type

  • 8.1 Immunomodulatory Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Proteasome Inhibitors
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Histone Deacetylase Inhibitors
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Monoclonal Antibody Drugs
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Steroids
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Men
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Women
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacies
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Indicators

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Amgen Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Bristol Myers Squibb
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Daiichi Sankyo Co.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Sanofi-Aventis Groupe (Genzyme Corporation)
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 SWOT Analysis
    • 16.3.5 Johnson & Johnson Services, Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Merck & Co., Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Novartis International AG
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Pfizer Inc.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 PHARMA MAR, S.A.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
    • 16.3.10 Takeda Pharmaceutical Company Limited.
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Teva Pharmaceutical Industries Ltd.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis